Zimbabwe has rejected a major US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years over Washington's insistence on confidential data.
The decision became public after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesperson later clarified that the US was requesting genetic material for research and commercial gain while was unwilling to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued talks to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Implications
This development comes after a comparable situation in Kenya, where a court blocked a similar deal with the US following concerns were filed about the security of citizens' medical information.
After resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to boost transparency and accountability.
According to statements, Sixteen African countries have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, without any corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research without any assurance that the resulting innovations would be accessible to our population should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its push of bilateral health agreements were disrupting frameworks previously established through the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This framework is intended to ensure that when a country provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our US partners on how subsequent collaboration could be structured in a way that honours the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but recommended that negotiations must proceed given that a large portion of the country's HIV programmes depended on foreign aid.
"In cases where technical issues exist, such as those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group added.
This impasse emphasises the continuing debate between receiving vital international aid and safeguarding a country's data in an ever more data-driven world.